Compare SKYX & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SKYX | MOLN |
|---|---|---|
| Founded | 2004 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Building Products | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.8M | 147.5M |
| IPO Year | 2014 | 2021 |
| Metric | SKYX | MOLN |
|---|---|---|
| Price | $0.86 | $3.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $4.00 | ★ $10.36 |
| AVG Volume (30 Days) | ★ 709.6K | 2.0K |
| Earning Date | 11-11-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,700,948.00 | N/A |
| Revenue This Year | $16.10 | N/A |
| Revenue Next Year | $27.95 | $450.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.78 | N/A |
| 52 Week Low | $0.83 | $3.52 |
| 52 Week High | $3.29 | $5.36 |
| Indicator | SKYX | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 23.92 | 42.21 |
| Support Level | N/A | $3.66 |
| Resistance Level | $1.29 | $4.21 |
| Average True Range (ATR) | 0.06 | 0.14 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 8.28 | 25.42 |
SKYX Platforms Corp operates in the business of developing proprietary technology that enables a quick and safe installation of electrical fixtures, such as light fixtures and ceiling fans. Its technology consists of a weight-bearing, fixable socket and a revolving plug for conducting electric power and supporting an electrical appliance attached to a wall or ceiling. The socket is comprised of a nonconductive body that houses conductive rings connectable to an electric power supply through terminals in its side exterior. The plug is also comprised of a nonconductive body that houses corresponding conductive rings, attaches to the socket via a male post, and is capable of feeding electric power to an appliance. It generates its income from lighting and heating products sold in the USA.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.